<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-47" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Axillary Lymphadenectomy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Toomey</surname>
            <given-names>Ariel E.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lewis</surname>
            <given-names>Catherine R.</given-names>
          </name>
          <aff>Norton Community Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ariel Toomey declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Catherine Lewis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-47.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Axillary lymphadenectomy is a procedure performed most commonly for breast cancer lymph node metastasis, and this activity focuses on breast cancer specifically. Once the standard of care for breast cancer axillary evaluation, it has decreased in frequency and has specific indications at present. This activity reviews the anatomy and indications for this procedure and highlights the role of the interprofessional team in forming a treatment plan for patients pre- and postoperatively.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for axillary lymphadenectomy.</p></list-item><list-item><p>Describe the technique of axillary lymphadenectomy.</p></list-item><list-item><p>Review the appropriate evaluation of the potential complications of axillary lymphadenectomy.</p></list-item><list-item><p>Explain interprofessional team strategies for improving care coordination and communication to advance axillary lymphadenectomy and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=47&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=47">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-47.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Axillary lymphadenectomy, or axillary dissection, is a procedure where a surgeon dissects out the lymph nodes within the axilla en bloc. This is done most commonly for cancer workups and treatment. This procedure used to be done widely, but it is done much more selectively in recent years with advances in early detection and treatment, as well as numerous studies showing no increased benefit to this procedure in certain circumstances. The most common disease process that this is done for is breast cancer. While the focus of this article will be on breast cancer, it is important to note that sentinel lymph node biopsy and axillary lymphadenectomy can be performed for lung cancer and melanoma as well.<xref ref-type="bibr" rid="article-47.r1">[1]</xref></p>
      </sec>
      <sec id="article-47.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>Axillary anatomy is very important to know for performing axillary lymphadenectomy. There are three levels of axillary lymph nodes. Typically, level one and level two lymph nodes are taken during this dissection. Level three nodes are not sought after in current times. Level one nodes are lateral to the pectoralis minor muscle, level two lymph nodes are deep to the pectoralis minor muscle, and level three lymph nodes are medial to the pectoralis minor muscle. Rotter's nodes are lymph nodes between the pectoralis major and minor muscles. The axillary fat pad is deep to the subcutaneous fat and does have a different appearance so that it is usually distinguishable. The borders of the axilla are especially important as they act as a guide to orient the surgeon during the procedure and indicate where the dissection should be performed. The important borders of the axilla are the axillary vein superiorly, which can act as the first structure to identify during an especially difficulty dissection.&#x000a0;The medial border is the chest wall. The pectoralis major and pectoralis minor make the anterior border. The axillary skin is the lateral border. The posterior border is the latissimus dorsi muscle. There are multiple nerves within this area that great care must be taken&#x000a0;to avoid injuring. The most likely injured is the intercostobrachial nerve. When this is transected, it causes paresthesias to the medial upper arm. The long thoracic nerve, thoracodorsal neurovascular bundle, and lateral thoracic artery are also within the region and can be at risk for injury. The long thoracic nerve innervates the serratus anterior muscle. Injury to the long thoracic nerve results in winged scapula and patients may complain of upper extremity weakness or decreased range of motion of the shoulder. The thoracodorsal nerve innervates the latissimus dorsi muscle, and injury causes loss of function.</p>
      </sec>
      <sec id="article-47.s4" sec-type="Indications">
        <title>Indications</title>
        <p>In most cases, axillary sentinel lymph node biopsy has taken the place of axillary dissection in clinically node-negative patients. Indications for axillary lymphadenectomy include<xref ref-type="bibr" rid="article-47.r2">[2]</xref>:</p>
        <p>Clinically positive axillary lymph nodes that have been proven with biopsy in a patient that is not planning on undergoing neoadjuvant chemotherapy</p>
        <p>Patients with inflammatory breast cancer</p>
        <p>Patients who do not meet guidelines for the Z0011 criteria</p>
        <p>Patients with three or more axillary sentinel nodes that are positive for cancer</p>
        <p>Persistently positive lymph nodes after neoadjuvant therapy</p>
        <p>Axillas with failed radiotracer and/or lymphazurin/methylene blue during sentinel lymph node biopsy</p>
        <p>Axillary lymph node recurrence after prior breast cancer treatment<xref ref-type="bibr" rid="article-47.r3">[3]</xref><xref ref-type="bibr" rid="article-47.r4">[4]</xref><xref ref-type="bibr" rid="article-47.r5">[5]</xref><xref ref-type="bibr" rid="article-47.r6">[6]</xref><xref ref-type="bibr" rid="article-47.r7">[7]</xref><xref ref-type="bibr" rid="article-47.r8">[8]</xref></p>
      </sec>
      <sec id="article-47.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are typically not any absolute contraindications to axillary lymphadenectomy. If a patient has recurrent breast disease or a second primary with a history of an axillary dissection on the same side, an axillary dissection is not usually performed for new cancer. In current times, most patients will be able to have a sentinel lymph node biopsy in place of a formal axillary dissection, except, of course, for the indications listed above. If a patient has distant metastasis, an axillary dissection is not usually necessary with evidence of grossly metastatic disease.&#x000a0;</p>
      </sec>
      <sec id="article-47.s6" sec-type="Equipment">
        <title>Equipment</title>
        <p>An operating suite is needed for this procedure, along with the necessary equipment for anesthesia, as well as standard surgical instrument sets. Typically a radiotracer probe is not needed for this procedure. It may be in the room if the initial procedure was a sentinel lymph node biopsy and was converted to an axillary lymphadenectomy, but is not used for this procedure.&#x000a0;</p>
      </sec>
      <sec id="article-47.s7" sec-type="Personnel">
        <title>Personnel</title>
        <p>General surgeons, surgical oncologists, or breast surgeons typically perform this procedure. This procedure is done in the operating room, typically with general anesthesia. The usual operating room personnel are required, including anesthesiology, surgical technologist, and circulating nurses. Pathologists will then review the specimen after the procedure is completed. Once pathology is back, surgeons, in combination with radiation and medical oncologists, will decide on the necessary next steps in treatment.</p>
      </sec>
      <sec id="article-47.s8" sec-type="Preparation">
        <title>Preparation</title>
        <p>These patients are typically brought to breast tumor board prior to surgery so that a prospective plan is made before taking the patients for surgery. The surgeon then obtains informed consent before the operation. This includes the patients with possible axillary dissection during a sentinel lymph node biopsy procedure, in addition to patients who had a planned axillary lymphadenectomy. Radiotracer and/or lymphazurin/methylene blue are not necessary for this procedure but may have been used if the initial procedure was a sentinel lymph node biopsy that was converted to axillary dissection.<xref ref-type="bibr" rid="article-47.r9">[9]</xref></p>
      </sec>
      <sec id="article-47.s9" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>The patient's axilla is prepped and draped in the usual sterile fashion. The patient is supine with the arm of the affected side at 90 to 100 degrees of abduction on an arm board. The landmark used superficially for the axillary incision is the inferior axillary hair line. An oblique incision is made, and electrocautery is typically used to dissect through the subcutaneous tissue to access the axillary fat pad once the clavipectoral fascia is incised. Once this is identified, many surgeons will identify the axillary vein and begin dissection inferior to this. Retraction is used to elevate the pectoralis muscles to dissect out the level two lymph nodes. Typically, most of this dissection can be performed bluntly. The axillary specimen is usually removed en bloc. The cavity is examined, and hemostasis is achieved as necessary, taking care to not injure any of the surrounding nerves or major vessels.&#x000a0;A small drain&#x000a0;may be left in place, with the exit point at a site other than the incision. The drain is sutured in place. The axillary incision is closed based on surgeon preference. Some sort of compressive dressing can be used postoperatively to provide some support and decrease seroma formation in addition to the drain.<xref ref-type="bibr" rid="article-47.r10">[10]</xref></p>
      </sec>
      <sec id="article-47.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Axillary lymphadenectomy does carry increased morbidity when compared to sentinel lymph node biopsy, which is, in part, why it is performed more selectively in recent years. Typical complications with any surgery include infection and bleeding. Complications specific to this procedure include temporarily decreased range of motion of the shoulder, hematoma, lymphedema, lymphocele, lymphatic fibrosis, lymphangiosarcoma, injury to vasculature, or nerves within the region, or axillary vein thrombosis. Drains are placed commonly after this procedure, and while not a complication in itself, prolonged need for the drain can be a complication. Typically after an axillary lymphadenectomy is performed, there is not a need for additional surgery in the same region, unless there is an axillary recurrence in the future.<xref ref-type="bibr" rid="article-47.r11">[11]</xref></p>
      </sec>
      <sec id="article-47.s11" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Axillary lymphadenectomy is done when there is already positive disease within the axilla. Typically this is done to ascertain the extent of the disease within the axilla, which is extremely important for staging. In turn, the status of the axillary nodes and stage of the patient plays a major part in the subsequent treatment that the patient will be receiving. This can include chemotherapy and radiation therapy. A ten lymph node minimum is considered an adequate axillary dissection, although if less are obtained, surgeons rarely go back to surgery for additional lymph nodes. Of note, once a patient has had an axillary dissection, care is taken to avoid IV or blood pressure recordings in that arm as there is an increased risk of lymphedema compared to sentinel lymph node biopsy. Postoperatively, patients are given arm exercises and can be referred to a lymphedema clinic if this does arise.<xref ref-type="bibr" rid="article-47.r12">[12]</xref><xref ref-type="bibr" rid="article-47.r5">[5]</xref></p>
      </sec>
      <sec id="article-47.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Breast cancer care requires an interprofessional team approach, including surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, nurse navigators, physical therapists, and more. These teams are crucial in formulating plans during breast tumor boards and in the aftercare of these patients for survivorship planning. Being up to date in all aspects of these specialties provides for the best patient care, improved patient outcomes, and overall enhances the team's performance when taking care of these patients.&#x000a0;</p>
      </sec>
      <sec id="article-47.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=47&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=47">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/47/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=47">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-47.s14">
        <fig id="article-47.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Axillary Lymph Nodes, Illustrated anatomy includes the deltopectoral glands, lateral group, subclavicular group, central group, subscapular group, pectoral group,&#x000a0;cutaneous collecting trunks, subareolar plexus, mammary collecting trunks, and mammary lymphatic ending in the subclavicular glands. Henry Vandyke Carter,<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://commons.wikimedia.org/w/index.php?search=gray+plate+607&#x00026;title=Special:MediaSearch&#x00026;go=Go&#x00026;type=image"> Public Domain</ext-link>, via Wikimedia Commons</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Gray607" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-47.s15">
        <title>References</title>
        <ref id="article-47.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Black</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Mittendorf</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Landmark trials affecting the surgical management of invasive breast cancer.</article-title>
            <source>Surg Clin North Am</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>501</fpage>
            <page-range>501-18</page-range>
            <pub-id pub-id-type="pmid">23464699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-47.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ling</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Iarrobino</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Champ</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Soran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beriwal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Regional Recurrence Rates With or Without Complete Axillary Dissection for Breast Cancer Patients with Node-Positive Disease on Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy.</article-title>
            <source>Adv Radiat Oncol</source>
            <year>2020</year>
            <season>Mar-Apr</season>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-170</page-range>
            <pub-id pub-id-type="pmid">32280815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-47.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Amina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>ZM</given-names>
              </name>
            </person-group>
            <article-title>[Normalization in axillary lymph node management after neoadjuvant therapy for breast cancer].</article-title>
            <source>Zhonghua Wai Ke Za Zhi</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-101</page-range>
            <pub-id pub-id-type="pmid">30704211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-47.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Barros</surname>
                <given-names>ACSD</given-names>
              </name>
              <name>
                <surname>de Andrade</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Extended Sentinel Node Biopsy in Breast Cancer Patients who Achieve Complete Nodal Response with Neoadjuvant Chemotherapy.</article-title>
            <source>Eur J Breast Health</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-105</page-range>
            <pub-id pub-id-type="pmid">32285030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-47.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costaz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rouffiac</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boulle</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Arnould</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Beltjens</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Desmoulins</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Peignaux</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ladoire</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jankowski</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Coutant</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>[Strategies in case of metastatic sentinel lymph node in breast cancer].</article-title>
            <source>Bull Cancer</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>107</volume>
            <issue>6</issue>
            <fpage>672</fpage>
            <page-range>672-685</page-range>
            <pub-id pub-id-type="pmid">31699399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-47.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Validating the ACOSOG Z0011 Trial Result: A Population-Based Study Using the SEER Database.</article-title>
            <source>Cancers (Basel)</source>
            <year>2020</year>
            <month>Apr</month>
            <day>11</day>
            <volume>12</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">32290437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-47.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cipolla</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valerio</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Grassi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Calamia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Latteri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Latteri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Graceffa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vieni</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Axillary Nodal Burden in Breast Cancer Patients With Pre-operative Fine Needle Aspiration-proven Positive Lymph Nodes Compared to Those With Positive Sentinel Nodes.</article-title>
            <source>In Vivo</source>
            <year>2020</year>
            <season>Mar-Apr</season>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>729</fpage>
            <page-range>729-734</page-range>
            <pub-id pub-id-type="pmid">32111777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-47.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dixon</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Cartlidge</surname>
                <given-names>CWJ</given-names>
              </name>
            </person-group>
            <article-title>Twenty-five years of change in the management of the axilla in breast cancer.</article-title>
            <source>Breast J</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-26</page-range>
            <pub-id pub-id-type="pmid">31854498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-47.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alvarado</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Mittendorf</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Teshome</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bold</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Gittleman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Beitsch</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Kivilaid</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harmer</surname>
                <given-names>QJ</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer.</article-title>
            <source>Ann Surg Oncol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>11</issue>
            <fpage>3510</fpage>
            <page-range>3510-3516</page-range>
            <pub-id pub-id-type="pmid">31297674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-47.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ung</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chua</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Barraclough</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Complete axillary dissection: a technique that still has relevance in contemporary management of breast cancer.</article-title>
            <source>ANZ J Surg</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>518</fpage>
            <page-range>518-21</page-range>
            <pub-id pub-id-type="pmid">16768781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-47.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kadayaprath</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Neha</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Use of Sentinel Lymph Node Biopsy and Early Physiotherapy to Reduce Incidence of Lymphedema After Breast Cancer Surgery: an Institutional Experience.</article-title>
            <source>Indian J Surg Oncol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-18</page-range>
            <pub-id pub-id-type="pmid">32205962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-47.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krag</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Julian</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Harlow</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Costantino</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ashikaga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Mamounas</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Jalovec</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Frazier</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Noyes</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Robidoux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scarth</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Wolmark</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>927</fpage>
            <page-range>927-33</page-range>
            <pub-id pub-id-type="pmid">20863759</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
